Citations

Clear

410 citation(s) found for "Shu, Yu".

Single dose versus multiple doses of rituximab for preemptive therapy of Epstein–Barr virus reactivation after hematopoietic cell transplantation
Jain, Tania , Grys, Thomas E. , Kung, Shu Ting, Shah, Vishal , Betcher, Jeffrey, Slack, James L., Leis, José F., Khera, Nandita , Noël, Pierre, Palmer, Jeanne , Sproat, Lisa Z., Shah, Vishal S, Betcher, Jeffrey A, Palmer, Jeanne M., Jain, Tania , Kosiorek, Heidi , Shah, Vishal , Grys, Thomas E

Mayo Clinic

Leukemia & Lymphoma | July 6, 2018 | Volume: 60 | Issue: 1 | Pages: 110-117

10.1080/10428194.2018.1459603 | PMID 29979906 Get It

Progression-Free Survival as a Surrogate End Point for Overall Survival in First-Line Diffuse Large B-Cell Lymphoma: An Individual Patient–Level Analysis of Multiple Randomized Trials (SEAL)
Shi, Qian , Schmitz, Norbert , Dixon, Jesse G. , Pfreundschuh, Michael , Seymour, John F. , Jaeger, Ulrich, Haïoun, Corinne , Tilly, Hervé , Ghesquières, Hervé , Merli, Francesco , Ziepert, Marita , Herbrecht, Raoul , Flament, Jocelyne, Coiffier, Bertrand , Flowers, Christopher R. , Cunningham, David , Fu, Tommy , Shi, Qian , Ou, Fang‐Shu , Habermann, Thomas M. , Dixon, Jesse G

Mayo Clinic

Journal of Clinical Oncology | July 5, 2018 | Volume: 36 | Issue: 25 | Pages: 2593-2602

10.1200/jco.2018.77.9124 | PMID 29975624 Get It

Purpose Overall survival (OS) is the definitive and best-established primary efficacy end point to evaluate diffuse large B-cell lymphoma (DLBCL) therapies, but it requires prolonged follow-up. An earlier end point assessed post-treatment would expedite clinical trial conduct and accelerate patient access to effective new therapies. Our objective was to formally evaluate progression-free survival (PFS) and PFS at 24 months (PFS24) as surrogate end points for OS in first-line DLBCL. Patients and Methods Individual patient data were analyzed from 7,507 patients from 13 multicenter randomized controlled trials of active treatment in previously untreated DLBCL, published after 2002, with sufficient PFS data to predict treatment effects on OS. Trial-level surrogacy examining the correlation of treatment effect estimates of PFS/PFS24 and OS was evaluated using both linear regression ( R2WLS) and Copula bivariable ( R2Copula) models. Prespecified criteria for surrogacy required either R2WLS or R2Copula ≥ 0.80 and neither < 0.7, with lower-bound 95% CI > 0.60. Results Trial-level surrogacy for PFS was strong ( R2WLS = 0.83; R2Copula = 0.85) and met the predefined criteria for surrogacy. At the patient level, PFS strongly correlated with OS. The surrogate threshold effect had a hazard ratio of 0.89. Surrogacy was consistent across comparisons with or without rituximab and with rituximab maintenance trials. Trial-level surrogacy for PFS24 was relatively strong ( R2WLS = 0.77; R2Copula = 0.78) but did not meet prespecified criteria. At the patient level, PFS24 significantly correlated with OS. The surrogate threshold effect had an odds ratio of 1.51. Conclusion This large pooled analysis of individual patient data supports PFS as a surrogate end point for OS in future randomized controlled trials evaluating chemoimmunotherapy in DLBCL. Use of this end point may expedite therapeutic development with the intent of bringing novel therapies to this patient population years before OS results are mature.
Characteristics of TBS-Extractable Hyperphosphorylated Tau Species: Aggregation Intermediates in rTg4510 Mouse Brain
DeTure, Michael , Ren, Yan, Ebrahim, Abdul-Shukkur, Kang, Dongcheul, Volbracht, Christiane , Pedersen, Jan T., Dickson, Dennis W. , Yen, Shu‐Hui, Lewis, Jada , Dickson, Dennis W , Sahara, Naruhiko , Knight, Joshua A.

Mayo Clinic

Journal of Alzheimer's Disease | June 4, 2018 | Volume: 33 | Issue: 1 | Pages: 249-263

10.3233/jad-2012-121093 | PMID 22941973 Get It

Novel Common Genetic Susceptibility Loci for Colorectal Cancer
Schmit, Stephanie L. , Edlund, Christopher K., Schumacher, Fredrick R. , Harrison, Tabitha A. , Huyghe, Jeroen R. , Qu, Chenxu, Melas, Marilena , Berg, David Van Den , Wang, Hansong, Tring, Stephanie, Plummer, Sarah J. , Alonso, M. Henar , Anton, Kristen , Aragaki, Aaron K. , Arndt, Volker , Barry, Elizabeth L. , Berndt, Sonja I. , Bloomer, Amanda M. , Boehm, Juergen , Brenner, Hermann , Brezina, Stefanie , Buchanan, Daniel D. , Butterbach, Katja, Caan, Bette J. , Carlson, Christopher S. , Castelao, Jose E. , Chang‐Claude, Jenny , Cheng, Ya‐Wen , Chin, Lee Soo, Church, Timothy R. , Correa, Marcia Cruz, Curtis, Keith R. , Duggan, David , Easton, Douglas F. , English, Dallas R. , Fischer, Rocky, Fritsche, Lars G. , Fuchs, Charles S. , Gago-Domínguez, Manuela , Gala, Manish , Gallinger, Steven , Gauderman, W. James, Giovannucci, Edward L. , Gogarten, Stephanie M. , González‐Villalpando, Clicerio, Gonzalez-Villalpando, Elena M., Greenson, Joel K. , Gsur, Andrea , Gunter, Marc J. , Haiman, Christopher A. , Hampe, Jochen , Harlid, Sophia , Harju, John F., Hayes, Richard B. , Hofer, Philipp , Hoffmeister, Michael , Huang, Shu-Chen, Huerta, José María , Hunter, David J., Idos, Gregory , Jackson, Rebecca D. , Jacobs, Eric J. , Jee, Sun Ha , Jenkins, Mark A. , Jia, Wei-Hua , Jiao, Shuo , Joshi, Amit D. , Kolonel, Laurence N. , Kono, Suminori , Krogh, Vittorio , Küehn, Tilman, Küry, Sébastien , LaCroix, Andrea Z. , Laurie, Cecelia , Lejbkowicz, Flavio, Lemire, Mathieu , Lenz, Heinz‐Josef , Levine, David , Li, Li , Lindor, Noralane M. , Liu, Yun-Ru, Lu, Yingchang , Luh, Frank , Ma, Jing , Mancao, Christoph , Manion, Frank J. , Markowitz, Sanford D. , Martín, Vicente , Matsuo, Keitaro , McDonnell, Kevin , McNeil, Caroline E, Murphy, Neil , Offit, Kenneth, Omichessan, Hanane , Cotoré, Jesús Paredes, Pérez‐Mayoral, Julyann, Rennert, Gad , Rennert, Hedy S., Riggs, Bridget M., Schafmayer, Clemens, Sellers, Thomas A. , Seminara, Daniela, Shibata, David , Siegel, Erin M. , Slattery, Martha L. , Stintzing, Sebastian , Taverna, Darin, Thibodeau, Stephen N. , Thomas, Duncan C. , Trichopoulou, Antonia , Duijnhoven, Fränzel J.B. van , Guelpan, Bethany van, Virtamo, Jarmo, Weinstein, Stephanie J. , Win, Aung Ko , Woods, Michael O. , Wu, Anna H. , Wu, Kana , Xiang, Yong-Bing , Zanke, Brent W., Zeng, Yi-Xin , Zhang, Ben , Zubair, Niha, Figueiredo, Jane C. , Lindblom, Annika , Moreno, Vı́ctor , Peters, Ulrike , Conti, David V. , Gruber, Stephen B. , Kühn, Tilman , Buchanan, Daniel D , Win, Aung K , Rennert, Gad , Hoffmeister, Michael , Arndt, Volker , English, Dallas R , Martín, Vicente , Moreno, Victor , Gunter, Marc J , Jenkins, Mark A , Van Den Berg, David J , Harrison, Tabitha A , Matsuo, Keitaro , Kury, Sebastien , Brenner, Hermann , Gago-Dominguez, Manuela , Hampe, Jochen , Murphy, Neil , Hayes, Richard B , Brezina, Stefanie , Conti, David V , Gong, Jian Feng , Albanes, Demetrius , Amos, Christopher I. , Bezieau, Stéphane , Bien, Stephanie A. , Boutron‐Ruault, Marie‐Christine , Campbell, Peter T. , Chan, Andrew T. , Chanock, Stephen Jacob , Cheng, Iona C. , Church, James M. , Coetzee, Gerhard A. , Cotterchio, Michelle , Feskens, Edith J. M. , FitzGerald, Liesel M. , Fortini, Barbara K. , Giles, Graham G. , Grady, William M. , Hopper, John L. , Hudson, Thomas J , Iwasaki, Motoki , Kooperberg, Charles , Li, Christopher I , Lieb, Wolfgang , Lin, Yi , Liu, Yun‐Ru , Loupakis, Fotios , Matsuda, Koichi , McNeil, Caroline E, Milne, Roger L. , Molina, Antonio José , Mukherjee, Bhramar , Newcomb, Polly A. , Palli, Domenico , Pharoah, Paul D.P. , Potter, John D. , Qu, Conghui , Raskin, Leon , Schoen, Robert E. , Severi, Gianluca , Shi, Wei , Shu, Xiao‐Ou , Southey, Melissa C. , Stadler, Zsofia , Stern, Mariana Carla , Tsugane, Shoichiro , Ulrich, Cornelia M. , Vijai, Joseph , White, Emily E. , Wolk, Alicja , Yen, Yun , Kweon, Sun-Seog , Zheng, Wei , Marchand, Loı̈c Le , Casey, Graham , Church, Timothy R , Caan, Bette J , Lindblom, Annika

Mayo Clinic

JNCI: Journal of the National Cancer Institute | April 30, 2018 | Volume: 111 | Issue: 2 | Pages: 146-157

10.1093/jnci/djy099 | PMID 29917119 Get It

Abstract Background Previous genome-wide association studies (GWAS) have identified 42 loci (P < 5 × 10−8) associated with risk of colorectal cancer (CRC). Expanded consortium efforts facilitating the discovery of additional susceptibility loci may capture unexplained familial risk. Methods We conducted a GWAS in European descent CRC cases and control subjects using a discovery–replication design, followed by examination of novel findings in a multiethnic sample (cumulative n = 163 315). In the discovery stage (36 948 case subjects/30 864 control subjects), we identified genetic variants with a minor allele frequency of 1% or greater associated with risk of CRC using logistic regression followed by a fixed-effects inverse variance weighted meta-analysis. All novel independent variants reaching genome-wide statistical significance (two-sided P < 5 × 10−8) were tested for replication in separate European ancestry samples (12 952 case subjects/48 383 control subjects). Next, we examined the generalizability of discovered variants in East Asians, African Americans, and Hispanics (12 085 case subjects/22 083 control subjects). Finally, we examined the contributions of novel risk variants to familial relative risk and examined the prediction capabilities of a polygenic risk score. All statistical tests were two-sided. Results The discovery GWAS identified 11 variants associated with CRC at P < 5 × 10−8, of which nine (at 4q22.2/5p15.33/5p13.1/6p21.31/6p12.1/10q11.23/12q24.21/16q24.1/20q13.13) independently replicated at a P value of less than .05. Multiethnic follow-up supported the generalizability of discovery findings. These results demonstrated a 14.7% increase in familial relative risk explained by common risk alleles from 10.3% (95% confidence interval [CI] = 7.9% to 13.7%; known variants) to 11.9% (95% CI = 9.2% to 15.5%; known and novel variants). A polygenic risk score identified 4.3% of the population at an odds ratio for developing CRC of at least 2.0. Conclusions This study provides insight into the architecture of common genetic variation contributing to CRC etiology and improves risk prediction for individualized screening.
Homocysteine Increases Tau Phosphorylation, Truncation and Oligomerization
Shirafuji, Norimichi, Hamano, Tadanori , Yen, Shu-Hui, Kanaan, Nicholas M. , Yoshida, Hirotaka , Hayashi, Kouji, Ikawa, Masamichi , Yamamura, Osamu , Kuriyama, Masaru, Nakamoto, Yasunari

Mayo Clinic

International Journal of Molecular Sciences | March 20, 2018 | Volume: 19 | Issue: 3 | Pages: 891

10.3390/ijms19030891 | PMID 29562600 Get It

Increased plasma homocysteinemia is considered a risk factor of dementia, including Alzheimer’s disease (AD) and vascular dementia. However, the reason elevated plasma homocysteinemia increases the risk of dementia remains unknown. A pathological hallmark of AD is neurofibrillary tangles (NFTs) that consist of pathologically phosphorylated tau proteins. The effect of homocysteine (Hcy) on tau aggregation was explored using human neuroblastoma M1C cells that constitutively express human wild-type tau (4R0N) under the control of a tetracycline off system, primary mouse cultured neurons, and by inducing hyperhomocysteinemia in a mouse model of tauopathy (HHCy mice). A wide range of Hcy concentrations (10–1000 µM) increased total tau and phosphorylated tau protein levels. Hcy activated glycogen synthase kinase 3, and cyclin dependent kinase 5, major tau phosphokinases, and inactivated protein phosphatase 2A, a main tau phosphatase. Hcy exhibited cytotoxic effects associated with enhanced activation of caspase. Truncation of tau in the C-terminus, the cleavage site of caspase 3 (i.e., D421, detected by the TauC3 antibody) was also increased. Total tau, phosphorylated tau, as well as C-terminal cleaved tau were increased in the sarkosyl insoluble tau fraction. Hcy also increased the level of tau oligomers, as indicated by the tau oligomer complex 1 (TOC1) antibody that specifically identifies oligomeric tau species, in the tris insoluble, sarkosyl soluble fraction. The levels of TOC1-positive oligomeric tau were increased in brain lysates from HHCy mice, and treating HHCy mice with S-adenosylmethionine, an intermediate of Hcy, reduced the levels of oligomeric tau to control levels. These observations suggest that Hcy increases the levels of phosphorylated tau as well as truncated tau species via caspase 3 activation, and enhanced tau oligomerization and aggregation.
Lightweight, compact, and high‐performance 3T MR system for imaging the brain and extremities
Foo, Thomas , Laskaris, E.T., Vermilyea, Mark, Xu, Minfeng , Thompson, Paul, Conte, Gene, Epps, Christopher Van, Immer, Christopher, Tan, Ek T. , Graziani, Dominic, Mathieu, Jean‐Baptise, Hardy, Christopher J., Schenck, John F., Fiveland, Eric, Stautner, Wolfgang , Ricci, Justin, Piel, Joseph E., Park, Keith, Hua, Yihe , Bai, Ye , Kagan, Alex, Stanley, David A. , Weavers, Paul T., Gray, Erin M. , Shu, Yunhong , Frick, Matthew A., Trzasko, Joshua D. , Foo, Thomas K F , Tan, Ek T , Gray, Erin, Trzasko, Joshua, Bernstein, Matt A , Thompson, Paul, Epps, Chris Van, Lee, Seung‐Kyun , Campeau, Norbert G. , Huston, John , Bernstein, Matt A.

Mayo Clinic

Magnetic Resonance in Medicine | March 15, 2018 | Volume: 80 | Issue: 5 | Pages: 2232-2245

10.1002/mrm.27175 | PMID 29536587 Get It

PurposeTo build and evaluate a small‐footprint, lightweight, high‐performance 3T MRI scanner for advanced brain imaging with image quality that is equal to or better than conventional whole‐body clinical 3T MRI scanners, while achieving substantial reductions in installation costs.MethodsA conduction‐cooled magnet was developed that uses less than 12 liters of liquid helium in a gas‐charged sealed system, and standard NbTi wire, and weighs approximately 2000 kg. A 42‐cm inner‐diameter gradient coil with asymmetric transverse axes was developed to provide patient access for head and extremity exams, while minimizing magnet‐gradient interactions that adversely affect image quality. The gradient coil was designed to achieve simultaneous operation of 80‐mT/m peak gradient amplitude at a slew rate of 700 T/m/s on each gradient axis using readily available 1‐MVA gradient drivers.ResultsIn a comparison of anatomical imaging in 16 patients using T2‐weighted 3D fluid‐attenuated inversion recovery (FLAIR) between the compact 3T and whole‐body 3T, image quality was assessed as equivalent to or better across several metrics. The ability to fully use a high slew rate of 700 T/m/s simultaneously with 80‐mT/m maximum gradient amplitude resulted in improvements in image quality across EPI, DWI, and anatomical imaging of the brain.ConclusionsThe compact 3T MRI system has been in continuous operation at the Mayo Clinic since March 2016. To date, over 200 patient studies have been completed, including 96 comparison studies with a clinical 3T whole‐body MRI. The increased gradient performance has reliably resulted in consistently improved image quality.
Reduced acoustic noise in diffusion tensor imaging on a compact MRI system
Tan, Ek T. , Hardy, Christopher J., Shu, Yunhong , In, Myung‐Ho , Guidon, Arnaud , Bernstein, Matt A. , Foo, Thomas , Bernstein, Matt A , Foo, Thomas K F , Tan, Ek T , Huston, John , In, Myung-Ho

Mayo Clinic

Magnetic Resonance in Medicine | October 3, 2017 | Volume: 79 | Issue: 6 | Pages: 2902-2911

10.1002/mrm.26949 | PMID 28971512 Get It

PurposeTo investigate the feasibility of substantially reducing acoustic noise while performing diffusion tensor imaging (DTI) on a compact 3T (C3T) MRI scanner equipped with a 42‐cm inner‐diameter asymmetric gradient.MethodsA‐weighted acoustic measurements were made using 10 mT/m‐amplitude sinusoidal waveforms, corresponding to echo‐planar imaging (EPI) echo spacing of 0.25 to 5.0 ms, on a conventional, whole‐body 3T MRI and on the C3T. Acoustic measurements of DTI with trapezoidal EPI waveforms were then made at peak gradient performance on the C3T (80 mT/m amplitude, 700 T/m/s slew rate) and at derated performance (33 mT/m, 10 to 50 T/m/s) for acoustic noise reduction. DTI was acquired in two different phantoms and in seven human subjects, with and without gradient‐derating corresponding to multi‐ and single‐shot acquisitions, respectively.ResultsSinusoidal waveforms on the C3T were quieter by 8.5 to 15.6 A‐weighted decibels (dBA) on average as compared to the whole‐body MRI. The derated multishot DTI acquisition noise level was only 8.7 dBA (at 13 T/m/s slew rate) above ambient, and was quieter than non‐derated, single‐shot DTI by 22.3 dBA; however, the scan time was almost quadrupled. Although derating resulted in negligible diffusivity differences in the phantoms, small biases in diffusivity measurements were observed in human subjects (apparent diffusion coefficient = +9.3 ± 8.8%, fractional anisotropy = +3.2 ± 11.2%, radial diffusivity = +9.4 ± 16.8%, parallel diffusivity = +10.3 ± 8.4%).ConclusionThe feasibility of achieving reduced acoustic noise levels with whole‐brain DTI on the C3T MRI was demonstrated. Magn Reson Med 79:2902–2911, 2018. © 2017 International Society for Magnetic Resonance in Medicine.
Clinical features and prognosis of thymic neuroendocrine tumours associated with multiple endocrine neoplasia type 1: A single‐centre study, systematic review and meta‐analysis
Ye, Lei , Wang, Weixi , Wang, Weixi, Ospina, Naykky Singh , Jiang, Lei , Christakis, Ioannis , Lu, Jieli , Zhou, Yulin , Cao, Yanan , Wang, Shu , Ning, Guang , Wang, Weiqing, Wang, Weiqing, Ospina, Naykky Singh , Wang, Weixi, Zhu, Wei Ping , Perrier, Nancy D. , Young, William F. , Wang, Weiqing, Wang, Weiqing, Singh Ospina, Naykky

Mayo Clinic

Clinical Endocrinology | September 20, 2017 | Volume: 87 | Issue: 6 | Pages: 706-716

10.1111/cen.13480 | PMID 28940393 Get It

SummaryObjectiveThymic neuroendocrine tumour (TH‐NET) accounts for almost 20% of multiple endocrine neoplasia type 1 (MEN1)‐associated mortality. Identifying risk factors for the development of these rare tumours and prognostic factors for clinical outcomes will be helpful in clinical practice.Design and PatientsWe performed a retrospective analysis of patients treated for TH‐NET associated with MEN1 in a single institution and meta‐analysis of literature reports. We used a fixed effect model to pool results across studies to evaluate the prevalence, clinical features and prognosis.ResultsTH‐NET was detected in 9 (7.4%) of 121 patients with MEN1 seen in our institution, and 5 (55.6%) were women. Seven additional studies were identified through a systematic review of the literature. The pool estimate of TH‐NET prevalence was 3.7% (n = 99) in MEN1 (n = 2710), sex ratio was 79:20 (male vs female), and the median age at diagnosis was 43.0 years (range, 16.0‐72.0 years). Forty‐three patients died with a median survival time of 8.4 years. Older age at diagnosis (HR = 1.4, 95% CI = 1.0‐1.8, P = .03), maximum tumour diameter (HR = 1.5, 95% CI = 1.0‐2.3, P = .04) and presence of metastasis (HR = 1.6, 95% CI = 1.0‐2.5, P = .04) were associated with worse outcome. A male predominance (91.9% vs 59.5%, P < .001) and history of smoking (59.0% vs 23.5%, P = .015) were more common in American/European series compared to Asian reports.ConclusionTH‐NET is a rare but fatal component of MEN1. Earlier detection of TH‐NET in patients with MEN1 may be recommended which should theoretically result in better outcomes. Different genetic backgrounds (race) appear to result in clinical difference.
Diagnostic criteria for adult‐onset leukoencephalopathy with axonal spheroids and pigmented glia due to CSF1R mutation
Yoshida, K., Mizuno, Toshiki , Kawarai, Toshitaka , Tada, Mari , Nozaki, Hiroaki , Ikeda, Shu‐ichi , Onodera, Osamu , Wszołek, Zbigniew K. , Mizuno, T , Kawarai, T , Wszolek, Z.K. , Onodera, Osamu , Konno, Takuya , Mizuta, Ikuko , Ikeuchi, Takeshi

Mayo Clinic

European Journal of Neurology | September 18, 2017 | Volume: 25 | Issue: 1 | Pages: 142-147

10.1111/ene.13464 | PMID 28921817 Get It

Background and purposeTo establish and validate diagnostic criteria for adult‐onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP) due to colony‐stimulating factor 1 receptor (CSF1R) mutation.MethodsWe developed diagnostic criteria for ALSP based on a recent analysis of the clinical characteristics of ALSP. These criteria provide ‘probable’ and ‘possible’ designations for patients who do not have a genetic diagnosis. To verify its sensitivity and specificity, we retrospectively applied our criteria to 83 ALSP cases who had CSF1R mutations (24 of these were analyzed at our institutions and the others were identified from the literature), 53 cases who had CSF1R mutation‐negative leukoencephalopathies and 32 cases who had cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL) with NOTCH3 mutations.ResultsAmong the CSF1R mutation‐positive cases, 50 cases (60%) were diagnosed as ‘probable’ and 32 (39%) were diagnosed as ‘possible,’ leading to a sensitivity of 99% if calculated as a ratio of the combined number of cases who fulfilled ‘probable’ or ‘possible’ to the total number of cases. With regard to specificity, 22 cases (42%) with mutation‐negative leukoencephalopathies and 28 (88%) with CADASIL were correctly excluded using these criteria.ConclusionsThese diagnostic criteria are very sensitive for diagnosing ALSP with sufficient specificity for differentiation from CADASIL and moderate specificity for other leukoencephalopathies. Our results suggest that these criteria are useful for the clinical diagnosis of ALSP.